⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27032225 | 0.79 | CYP4F2 (0.41) | — | |
| SCHEMBL27777245 | 0.79 | CES2 (0.41) | — | |
| SCHEMBL28112512 | 0.78 | — | — | |
| SCHEMBL8165085 | 0.75 | — | — | |
| SCHEMBL1895685 | 0.75 | — | — | |
| SCHEMBL28429573 | 0.73 | CES2 (0.30) | — | |
| SCHEMBL27790429 | 0.72 | MEN1 (0.30) | — | |
| SCHEMBL3202946 | 0.72 | — | — | |
| SCHEMBL27400644 | 0.71 | — | — | |
| SCHEMBL2887410 | 0.71 | POLB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190300473-A1 | COMPOSITION COMPRISING 1-CHLORO-2,2-DIFLUOROETHANE | ARKEMA FRANCE (FR) | 2019-10-03 | — | — | US | claimed |
| CN-108774147-A | A kind of N- aryl carboxamides prepared as formylation reagent using bromo difluoro acetate ethyl ester | 温州大学 | 2018-11-09 | — | — | CN | claimed |
| EP-4048265-A1 | METHODS OF TREATING CANCER USING ANDROGEN RECEPTOR ANTAGONISTS | Garvan Institute of Medical Research (AU) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021077174-A1 | METHODS OF TREATING CANCER USING ANDROGEN RECEPTOR ANTAGONISTS | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-04-29 | — | — | WO | disclosed |
| US-20190300473-A1 | COMPOSITION COMPRISING 1-CHLORO-2,2-DIFLUOROETHANE | ARKEMA FRANCE (FR) | 2019-10-03 | — | — | US | disclosed |
| EP-2563771-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS INC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8754227-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2563771-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130005776-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| CN-102666507-A | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2012-09-12 | — | — | CN | disclosed |
| US-8236962-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| CN-1863773-A | Tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-15 | — | — | CN | disclosed |
| WO-2006095359-A1 | SYNTHESIS OF 2-DEOXY-2, 2-DI FLUORO-D-RIBO FURANOSE-3, 5 DI(4-METHY/4-NITRO-CHLORO)BENZOATE AND ITS CONVERSION TO GEMCITABINE HYDROCHLORIDE THEREOF | SMS PHARMACEUTICALS LIMITED (IN) | 2006-09-14 | — | — | WO | disclosed |
| CN-1412181-A | Carboxylic acid derivatives inhibiting the binding of integrins to their receptors | TEXAS BIOTECHNOLOGIES CORP (US) | 2003-04-23 | — | — | CN | disclosed |
| CN-1360498-A | Carboxylic acid derivs. that inhibit binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORP (US) | 2002-07-24 | — | — | CN | disclosed |
| CN-1270165-A | Preparation of difluorobenzoethylketone derivatives | SS PHARMACEUTICAL CO (JP) | 2000-10-18 | — | — | CN | disclosed |
| CN-1152910-A | Difluorostatone antiviral agents | MERRELL PHARMA INC (US) | 1997-06-25 | — | — | CN | disclosed |
| CN-1142830-A | Macrocyclic difluorostatone derivatives useful as antiviral agents | MERRELL DOW PHARMA (US) | 1997-02-12 | — | — | CN | disclosed |
| CN-1031880-C | Novel analogs of peptidase substrates | MERRELL DOW PHARMA (US) | 1996-05-29 | — | — | CN | disclosed |
| CN-1043504-A | The novel analogs of peptidase substrates | MERRELL DOW PHARMA (US) | 1990-07-04 | — | — | CN | disclosed |